Chimeric antigen receptor targeting PD-l1 and t cell therapeutic agent expressing same

CAR-T cells engineered to bind PD-L1 and express cytokines upon activation address the limitations of CAR-T cell therapy by enhancing specificity and reducing toxicity, offering improved anticancer efficacy against solid tumors.

WO2024248490A1PCT designated stage expired Publication Date: 2024-12-05AJOU UNIV IND ACADEMIC COOP FOUND
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007365
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-29
Filing Date
2024-05-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current CAR-T cell therapy faces challenges such as toxicity, limited efficacy against solid cancers, resistance in B-cell malignancies, and short durability, necessitating improved strategies for enhanced anticancer effects and reduced side effects.

Method used

Development of CAR-T cells expressing a chimeric antigen receptor that specifically binds to PD-L1, combined with an inducible cytokine domain to selectively express cytokines like IL-2 upon activation, enhancing T cell killing ability and minimizing cytokine release syndrome.

Benefits of technology

The approach significantly improves the specificity and effectiveness of CAR-T cells against tumor cells, maintaining efficacy while reducing toxicity and side effects, particularly against solid tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007365_05122024_PF_FP_ABST
    Figure KR2024007365_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a chimeric antigen receptor (CAR) binding to PD-L1 of tumor cells and a composition for treating cancer using T cells transformed with an anti-PD-L1 CAR and provides T cells expressing a chimeric antigen receptor binding specifically to PD-L1 overexpressed in various solid cancers. Moreover, in the present invention, T cells are provided with a means capable of selectively expressing a cytokine increasing anticancer efficacy together with a site encoding an anti-PD-L1 chimeric antigen receptor. In addition, the present invention provides a cell therapeutic composition for preventing or treating cancer, the composition comprising T cells expressing the anti-PD-L1 chimeric antigen receptor prepared according to the present invention.
Need to check novelty before this filing date? Find Prior Art

Description

Chimeric antigen receptor targeting PD-L1 and T cell therapy expressing it

[0001] The present invention relates to a composition for treating cancer using a chimeric antigen receptor (CAR) that binds to PD-L1 of a tumor cell and a T cell transformed with an anti-PD-L1 CAR.

[0002] Chimeric antigen receptor (CAR)-T cells have revolutionized cell therapy by demonstrating effective and sustained clinical treatment for hematological malignancies. Chimeric antigen receptors are engineered synthetic receptors that activate T lymphocytes to recognize and eliminate cancer cells expressing specific target antigens. CAR binding to target antigens expressed on the cell surface results in active T cell activation and potent anticancer effects.

[0003] Building on the groundbreaking success of anti-CD19 CAR-T cells for B-cell hematological malignancies, the U.S. Food and Drug Administration (FDA) approved chimeric antigen receptor-based cell therapies in 2017. However, CAR-T cell therapies still face many challenges, including life-threatening CAR-T cell-induced toxicities, limited efficacy against solid tumors compared to hematological malignancies, resistance to B-cell malignancies, and limited persistence. Therefore, several different approaches have been attempted recently, including combining CAR-T cell therapy with other anticancer therapies or utilizing innovative CAR engineering strategies to improve anticancer efficacy, extend clinical efficacy duration, and attenuate toxicity.

[0004] PD-L1 (Programmed death-ligand 1) is a 40 kDa integral membrane protein. Cancer cells, in particular, overexpress PD-L1 to evade attacks by tumor antigen-specific T cells. PD-L1 overexpressed in cancer cells binds to PD-1, a PD-L1 receptor expressed on tumor antigen-specifically activated T cells, and suppresses the activation of tumor antigen-specific T cells through PD-1 / PD-L1 signaling. Therefore, antibody therapeutics (immune checkpoint inhibitors) that can suppress PD-1 / PD-L1 signaling have been developed and are currently actively used as treatments that can more effectively eliminate solid tumors. In addition, in order to increase the efficacy of CAR-T cells against solid tumors, the development of a new concept of CAR-T cell therapy to overcome the tumor microenvironment of immunosuppressed solid tumors is also actively underway by expressing not only chimeric antigen receptors that bind to tumor cell antigens but also various interleukins or chemokines with anticancer effects.

[0005] Against this backdrop, the inventors of the present invention took advantage of the fact that PD-L1 is overexpressed in various tumor cells and created CAR-T cells by additionally introducing an interleukin gene that enhances the anticancer effect into a chimeric antigen receptor using an antibody that binds to the PD-L1. The interleukin gene is not constantly expressed, but is expressed at the time of T cell activation, thereby enhancing the killing ability of T cells while simultaneously activating other antitumor immune cells, such as natural killer cells and macrophages, while minimizing side effects such as cytokine release syndrome. It was confirmed that the CAR-T cells designed with such enhanced function have cytotoxic ability specifically toward tumor cells expressing PD-L1.

[0006] [Prior Art Literature]

[0007] [Patent Document]

[0008] Korean Patent Publication No. 10-2019-0082241 (published on July 9, 2019)

[0009] The purpose of the present invention is to provide T cells expressing a chimeric antigen receptor that specifically binds to PD-L1, which is overexpressed in various solid cancers. Furthermore, the present invention provides T cells with a means for selectively expressing cytokines that enhance anticancer efficacy, in addition to a region encoding the anti-PD-L1 chimeric antigen receptor. Furthermore, the present invention provides a cell therapy composition for the prevention or treatment of cancer, comprising a T cell expressing the anti-PD-L1 chimeric antigen receptor produced according to the present invention.

[0010] The present invention provides a vector for producing T cells expressing a chimeric antigen receptor comprising an anti-PD-L1 scFv domain and an inducible cytokine domain.

[0011] In addition, the present invention provides a T cell that expresses a chimeric antigen receptor including an anti-PD-L1 scFv transfected with the vector and selectively expresses a cytokine depending on whether the T cell is activated, and a cell therapeutic agent composition for preventing or treating cancer using the same.

[0012] According to the present invention, an anti-PD-L1 chimeric antigen receptor comprising an anti-PD-L1 scFv domain is an antibody domain that specifically binds to PD-L1 specifically expressed in cancer cells, and T cells transformed with the anti-PD-L1 chimeric antigen receptor not only have improved specificity for tumor cells, but also have significantly improved cytotoxic effects as an inducible cytokine domain that selectively expresses cytokines depending on whether cells are activated is simultaneously transformed, thereby producing T cells expressing a chimeric antigen receptor.

[0013] Figure 1 is a schematic diagram showing the DNA region of each domain expressing the anti-PD-L1 chimeric antigen receptor according to the present invention.

[0014] FIG. 2 is a schematic diagram showing the DNA region of each domain additionally including an inducible cytokine domain in the anti-PD-L1 chimeric antigen receptor according to the present invention.

[0015] Figure 3 is a schematic diagram of a lentiviral vector for expressing an anti-PD-L1 chimeric antigen receptor construct according to the present invention.

[0016] Figure 4 is a schematic diagram showing that the anti-PD-L1 chimeric antigen receptor according to the present invention is expressed on the surface of a T cell.

[0017] Figure 5 shows the results of measuring the cytotoxic effect of T cells expressing an anti-PD-L1 chimeric antigen receptor according to the present invention on MDA-MB-231 cells, a PD-L1 expressing breast cancer cell line.

[0018] The terms used in this specification have been selected from widely used, current terms, taking into account the functions of the present invention. However, these terms may vary depending on the intentions of those skilled in the art, precedents, the emergence of new technologies, etc. Furthermore, in certain cases, terms may be arbitrarily selected by the applicant, and in such cases, their meanings will be described in detail in the relevant description of the invention. Therefore, the terms used in this invention should not be defined simply as names, but rather based on their inherent meanings and the overall content of the present invention.

[0019] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and shall not be interpreted in an idealized or overly formal sense unless explicitly defined herein.

[0020] Hereinafter, the present invention will be described in more detail.

[0021] The present invention provides a vector for producing T cells expressing a chimeric antigen receptor comprising an anti-PD-L1 scFv domain and an inducible cytokine domain.

[0022] The above chimeric antigen receptor comprises an anti-PD-L1 scFv region, a CD8 TM (transmembrane) region, a 4-1BB region, and a CD3ζ (zeta) region, and is produced as a vector comprising an antibody region binding to PD-L1, a cell membrane penetrating domain, and a domain for T cell transduction and activation.

[0023] The above anti-PD-L1 scFv region may be composed of a light chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 2, or a light chain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 4, or a light chain consisting of an amino acid sequence represented by SEQ ID NO: 5 and a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 6.

[0024] The above anti-PD-L1 scFv domain may sequentially include a gene encoding a light chain of anti-PD-L1 scFv represented by SEQ ID NO: 8 and a gene encoding a heavy chain of anti-PD-L1 scFv represented by SEQ ID NO: 9, or sequentially include a gene encoding a light chain of anti-PD-L1 scFv represented by SEQ ID NO: 10 and a gene encoding a heavy chain of anti-PD-L1 scFv represented by SEQ ID NO: 11, or sequentially include a gene encoding a light chain of anti-PD-L1 scFv represented by SEQ ID NO: 12 and a gene encoding a heavy chain of anti-PD-L1 scFv represented by SEQ ID NO: 13.

[0025] The above vector further comprises a CD8 TM (transmembrane) domain, a 4-1BB domain, and a CD3ζ (zeta) domain sequentially after the anti-PD-L1 scFv domain. The CD8 TM (transmembrane) domain is composed of a base sequence represented by SEQ ID NO: 18, the 4-1BB domain is composed of a base sequence represented by SEQ ID NO: 19, and the CD3ζ (zeta) domain is composed of a base sequence represented by SEQ ID NO: 20.

[0026] The inducible cytokine domain sequentially comprises a Nuclear factor of activated T cells (NFAT) binding motif and a gene encoding a cytokine. The cytokine may be any one selected from IL-2, IL-12, IL-7, IL-15, or IL-18.

[0027] Specifically, the inducible cytokine domain may be composed of a base sequence represented by SEQ ID NO: 14 that sequentially includes a NFAT (Nuclear factor of activated T cells) binding motif and a nucleotide encoding IL-2 so as to enable selective expression of IL-2.

[0028] In addition, the present invention provides a T cell that selectively expresses cytokines depending on whether the T cell is activated while expressing a chimeric antigen receptor comprising an anti-PD-L1 scFv transfected with the above vector.

[0029] The above T cells are CD4 isolated from monocytes + / CD8 + T cells stimulated with anti-CD3 and anti-hCD28 in the type.

[0030] In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer, which comprises a transformed T cell expressing on its surface a chimeric antigen receptor comprising an anti-PD-L1 scFv manufactured according to the present invention and comprising an inducible cytokine domain.

[0031] The above cancers are leukemia, acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic leukemia, chronic myeloblastic (granulocytic) leukemia, chronic lymphocytic leukemia, polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's disease, multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary It may be one or more diseases selected from among adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, cholangiocarcinoma, cholangiocarcinoma, seminoma, embryogenic carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

[0032] The above pharmaceutical composition may be prepared in unit dose form by formulating it using a pharmaceutically acceptable carrier or may be prepared by placing it in a multi-dose container.

[0033] The pharmaceutically acceptable carriers mentioned above are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.

[0034] In the present invention, the content of the additive included in the pharmaceutical composition is not particularly limited and can be appropriately adjusted within the content range used in conventional formulations.

[0035] In the present invention, the vector is a tool that enables stable transfection of cells, and the vector enables incorporation of the transgene(s) into the cellular genome. Preferably, such a vector has a positive selection marker, and a suitable positive selection marker includes any gene that allows cells to grow under conditions that kill cells that do not express the gene. Non-limiting examples may include antibiotic resistance. Additionally, the vector is a plasmid vector, and more specifically, the vector is a viral vector, and can be replaced with any suitable vector by a person skilled in the art, and preferably, the vector may be a lentiviral vector, a retroviral vector, a DNA vector, a plasmid, an RNA vector, an adenovirus vector, or an adenovirus-associated vector, but is not limited thereto.

[0036] In the present invention, the term "protein" is used interchangeably with "peptide" and "polypeptide" and refers to a compound having amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limitation on the maximum number of amino acids that can comprise the sequence of a protein or peptide. A polypeptide includes any peptide or protein having two or more amino acids linked to each other by peptide bonds. The term as used herein refers to both chains, with shorter chains also commonly referred to as peptides, oligopeptides, and oligomers in the art, and longer chains generally referred to as proteins in the art, of which there are many types. A "polypeptide" includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, etc. Polypeptides include natural peptides, It includes a recombinant peptide, a synthetic peptide, or a combination thereof.

[0037] In the present invention, nucleotide is commonly used with the same meaning as polynucleotide, and includes DNA and RNA. The polynucleotide is a nucleic acid, which is a polymer of nucleotides, and the polynucleotide can be hydrolyzed into monomeric nucleotides. The polynucleotide includes, but is not limited to, any nucleic acid sequence obtained by any means available in the art, including cloning nucleic acid sequences from a recombinant library or cellular genome using conventional cloning techniques and polymerase chain reaction (PCR), and synthetic means.

[0038] Hereinafter, to aid understanding of the present invention, experimental examples and examples will be described in detail. However, the following experimental examples and examples are merely illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental examples and examples of the present invention are provided to more fully explain the present invention to those of average skill in the art.

[0039]

[0040] Example 1. Production of anti-PD-L1 chimeric antigen receptor

[0041] According to the present invention, the anti-PD-L1 chimeric antigen receptor (CAR) was produced by referencing the anti-CD-19 CAR configuration based on a genetic database as shown in Fig. 1, and producing a genetic construct encoding the anti-PD-L1 CAR. In this embodiment, as one embodiment of the CAR, it was designed to sequentially include a single chain variable fragment (scFv) region that binds to PD-L1, a CD8 TM (transmembrane) region, a 4-1BB region, and a CD3ζ (zeta) region. The scFv domain was designed to be exposed outside of the cell, and was produced in three types to have the configurations shown in Table 1 below. Specifically, the anti-PD-L1 CAR according to the present invention may be of type A consisting of a light chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 2 as an anti-PD-L1 scFv region, or of type B consisting of a light chain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 4, or of type C consisting of a light chain consisting of an amino acid sequence represented by SEQ ID NO: 5 and a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 6.

[0042] 타입아미노산 서열SEQ. No.A경쇄(light chain)DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK1중쇄(heavy chain)EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS2B경쇄(light chain)EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK3중쇄(heavy chain)EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS4C경쇄(light chain)QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL5중쇄(heavy chain)EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS6

[0043]

[0044] The anti-PD-L1 CAR according to the present invention includes a CD8 TM (transmembrane) region as a cell membrane-penetrating region. The CD8 TM (transmembrane) region includes an amino acid sequence represented by SEQ ID NO: 15. The anti-PD-L1 CAR according to the present invention includes a 4-1BB region composed of an amino acid sequence represented by SEQ ID NO: 16 and a CD3ζ (zeta) region composed of an amino acid sequence represented by SEQ ID NO: 17, and the 4-1BB region and the CD3ζ (zeta) region are designed to be expressed inside a cell.

[0045] As shown in FIG. 1, the anti-PD-L1 CAR gene construct according to the present invention was produced to sequentially include a gene encoding a light chain of anti-PD-L1 scFv, a linker sequence, a gene encoding a heavy chain of anti-PD-L1 scFv, a CD8 TM (transmembrane) domain, a 4-1BB domain, and a CD3ζ (zeta) domain.

[0046] The above CAR gene construct type A includes a gene encoding a light chain of anti-PD-L1 scFv represented by SEQ ID NO: 8, and a gene encoding a heavy chain of anti-PD-L1 scFv represented by SEQ ID NO: 9.

[0047] The above CAR gene construct type B includes a gene encoding a light chain of anti-PD-L1 scFv represented by SEQ ID NO: 10, and a gene encoding a heavy chain of anti-PD-L1 scFv represented by SEQ ID NO: 11.

[0048] The above CAR gene construct type C includes a gene encoding a light chain of anti-PD-L1 scFv represented by SEQ ID NO: 12, and a gene encoding a heavy chain of anti-PD-L1 scFv represented by SEQ ID NO: 13.

[0049] The CD8 TM (transmembrane) domain is composed of a base sequence represented by SEQ ID NO: 18. The 4-1BB domain is composed of a base sequence represented by SEQ ID NO: 19. The CD3ζ (zeta) domain is composed of a base sequence represented by SEQ ID NO: 20.

[0050] Additionally, the anti-PD-L1 CAR gene construct according to the present invention may additionally include an inducible cytokine domain. The inducible cytokine domain is not constantly expressed, but is designed to be expressed in response to the activity of T cells infected with the chimeric antigen receptor according to the present invention, and is designed to prevent toxicity and inflammation caused by excessive cytokines.

[0051] In one embodiment of the present invention, as shown in FIG. 2, the 3' end of the anti-PD-L1 CAR configuration includes an inducible IL-2 domain sequentially including a NFAT (Nuclear factor of activated T cells) binding motif and a nucleotide encoding IL-2. The gene encoding the inducible IL-2 domain is configured by the base sequence represented by SEQ ID NO: 14. The gene encoding the inducible IL-2 domain can selectively induce the expression of IL-2 (interleukin-2) by including the NFAT (Nuclear factor of activated T cells) binding motif, and the IL-2 expressed through the inducible IL-2 domain is configured by the amino acid sequence represented by SEQ ID NO: 7.

[0052]

[0053] Example 2. Production of anti-PD-L1 CAR hematopoietic vector and lentivirus

[0054] A vector expressing the anti-PD-L1 CAR according to the present invention was constructed, and a lentivirus was used as a delivery vehicle. As shown in Fig. 3, the third-generation lentiviral vector pSL-BBZ was used as the basic backbone. The anti-PD-L1 CAR construct of the present invention was inserted into the vector.

[0055] In the above anti-PD-L1 CAR construct, a gene encoding the light chain of anti-PD-L1 scFv and a gene encoding the heavy chain of anti-PD-L1 scFv are located between the Bam H1 site and the Xho I site. In addition, the CAR construct is designed to express an EGFP (Enhanced Green Fluorescent Protein) sequence at the end so that expression can be confirmed experimentally.

[0056] The synthesized gene was subcloned into a lentiviral plasmid vector via polymerase chain reaction. Finally, the accuracy of the gene sequence was confirmed through base sequence sequencing using specific primers of the cloned plasmid. In addition, the nucleotide sequences and regulatory regions of cytokine genes such as IL-2, IL-12, IL-7, IL-15, or IL-18 were confirmed in the genetic database and synthesized, and subcloned into a lentiviral plasmid vector using the same method as above to finally produce an anti-PD-L1 CAR construct.

[0057] In this example, an anti-PD-L1 CAR construct was produced to sequentially include an inducible IL-2 domain sequentially including a NFAT (Nuclear factor of activated T cells) binding motif and a nucleotide encoding IL-2 in the CAR gene construct type C.

[0058] 3 μg of lentiviral vector designed to include the above anti-PD-L1 CAR construct was transfected into HEK293T cells (5 Y 10) using Lipofectamine (Thermo Scientific #R0531). 6 (cells) were infected. After culturing for 48 hours, the supernatant was collected and only virus particles were purified through a 0.45 μm filter. The purified virus particles were concentrated by ultracentrifugation at 28,000 rpm for 2 hours.

[0059]

[0060] Example 3. Isolation and activation of human T cells

[0061] To produce T cells expressing the anti-PD-L1 CAR according to the present invention, mononuclear cells were isolated from human peripheral blood. CD8 mononuclear cells were isolated from peripheral blood mononuclear cells using magnetic aggregation cell sorting (MACS). + T cells were isolated and stimulated with anti-hCD3 and anti-hCD28-coated immunobeads at a bead-to-cell ratio of 1:1 for 24 to 36 hours, and isolated CD4 - / CD8 + / CD3 + It was prepared with T cells.

[0062]

[0063] Example 4. Production of Anti-PD-L1 CAR-expressing T cells

[0064] In Example 3, the activated T cells were cultured with concentrated anti-CAR lentiviral vectors in a 48-well plate flat plate coated with Novo Nectin (Novoprotein) at 32°C. Six to seven days after transduction, the immune beads were removed, and the T cells were seeded at a cell density of 0.5 X 10 6 / ml to 2 Υ 10 6 / mL was adjusted every 3 days.

[0065]

[0066] Example 5. Cytotoxicity of anti-PD-L1 CAR T cells against PD-L1+ cancer cell lines

[0067] In order to confirm the killing effect of T cells expressing the anti-PD-L1 CAR manufactured according to the present invention on cancer cells, the killing effect on MDA-MB-231 cells, a breast cancer cell line, was evaluated. For comparison, T cells expressing the anti-CD-19 CAR were used as a control group. As shown in Fig. 1, the anti-CD-19 CAR used the anti-CD-19 CAR composition, and the CAR expressing T cells were produced using lentivirus in the same manner as the anti-PD-L1 CAR. MDA-MB-231 cells were seeded in a 96-well plate at 2 X 10 4 cells / mL and cultured in DMEM (Dulbecco's Modified Eagle's Medium) containing FBS for 24 hours. T cells transfected with each CAR were added to wells at various ratios and cultured at 37°C for 4 or 24 hours. The medium was removed from the wells after culture was completed, and 50 μl / well of 0.2% MTT (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) was added, and cultured in an incubator at 37°C for 2 hours. After removing the supernatant, 100 μl / well of DMSO (dimethyl sulfoxide) was added, and the suspension was made for 5 minutes to dissolve the formazan produced, and the absorbance was measured at 570 nm using a microplate reader to determine the apoptosis of cancer cells.

[0068] As shown in Fig. 5, when T cells transformed with each CAR were reacted with cancer cells, it was confirmed that the cytotoxicity did not change significantly even when the ratio of effector (E) T cells to target (T) cancer cells (E:T ratio) changed after 4 hours. When reacted for 24 hours, the death rate of cancer cells reacted with anti-CD-19 CAR T cells was found to decrease rapidly when the E:T ratio changed from 10:1 to 1:4. On the other hand, the death rate of cancer cells reacted with anti-PD-L1 CAR T cells was found to be significantly superior even when the E:T ratio changed from 10:1 to 1:4.

[0069] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. In other words, the substantial scope of the present invention is defined by the appended claims and their equivalents.

[0070] Numerical ranges are inclusive of the values ​​defined in the ranges above. Any maximum numerical limitation given throughout this specification includes any lower numerical limitation, as if that lower numerical limitation were explicitly stated. Any minimum numerical limitation given throughout this specification includes any higher numerical limitation, as if that higher numerical limitation were explicitly stated. Any numerical limitation given throughout this specification will include any better numerical range within the broader numerical range, as if that narrower numerical limitation were explicitly stated.

Claims

1. A vector for producing T cells expressing a chimeric antigen receptor comprising an anti-PD-L1 scFv domain and an inducible cytokine domain.

2. A vector according to claim 1, characterized in that the chimeric antigen receptor comprises an anti-PD-L1 scFv region, a CD8 TM (transmembrane) region, a 4-1BB region, and a CD3ζ (zeta) region.

3. In the second paragraph, the anti-PD-L1 scFv region is It is composed of a light chain consisting of an amino acid sequence represented by sequence number 1 and a heavy chain consisting of an amino acid sequence represented by sequence number 2, or It is composed of a light chain consisting of an amino acid sequence represented by sequence number 3 and a heavy chain consisting of an amino acid sequence represented by sequence number 4, or A vector characterized by comprising a light chain composed of an amino acid sequence represented by sequence number 5 and a heavy chain composed of an amino acid sequence represented by sequence number 6.

4. In the first paragraph, the anti-PD-L1 scFv domain is Sequentially comprising a gene encoding a light chain of anti-PD-L1 scFv represented by SEQ ID NO: 8, and a gene encoding a heavy chain of anti-PD-L1 scFv represented by SEQ ID NO: 9, or Sequentially comprising a gene encoding a light chain of anti-PD-L1 scFv represented by SEQ ID NO: 10, and a gene encoding a heavy chain of anti-PD-L1 scFv represented by SEQ ID NO: 11, or A vector characterized by sequentially including a gene encoding a light chain of anti-PD-L1 scFv represented by SEQ ID NO: 12 and a gene encoding a heavy chain of anti-PD-L1 scFv represented by SEQ ID NO:

13.

5. A vector according to claim 1, characterized in that the vector additionally sequentially comprises a CD8 TM (transmembrane) domain, a 4-1BB domain, and a CD3ζ (zeta) domain after the anti-PD-L1 scFv domain.

6. In paragraph 5, The above CD8 TM (transmembrane) domain is composed of a base sequence represented by sequence number 18, The above 4-1BB domain is composed of a base sequence represented by sequence number 19, A vector characterized in that the CD3ζ(zeta) domain is composed of a base sequence represented by sequence number 20.

7. A vector according to claim 1, characterized in that the inducible cytokine domain sequentially includes a NFAT (Nuclear factor of activated T cells) binding motif and a gene encoding a cytokine.

8. A vector according to claim 7, characterized in that the cytokine is any one selected from among IL-2, IL-12, IL-7, IL-15, and IL-18.

9. A vector according to claim 1, characterized in that the inducible cytokine domain is composed of a base sequence represented by SEQ ID NO:

14.

10. A vector according to claim 1, characterized in that the vector is a lentiviral vector.

11. A T cell transfected with any one of the vectors of clauses 1 to 10.

12. In the 11th paragraph, the T cell is CD4 isolated from mononuclear cells. + / CD8 + A T cell characterized by being a T cell stimulated with anti-CD3 and anti-hCD28 in the type.

13. A pharmaceutical composition for preventing or treating cancer comprising the T cell of Article 11.

Citation Information

Patent Citations

  • Organic electroluminescent materials and devices

    KR1020220111668A

  • Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use

    WO2018057585A1

  • Neoantigens expressed in multiple myeloma and their uses

    WO2021161245A1

  • Inducible cytokine prodrug and PD-1 / PD-l1 combination therapy

    WO2023023065A1